Targeting the epidermal growth factor receptor: Exploring the potential of novel inhibitor N-(3-Ethynylphenyl)-6, 7-bis (2-methoxyethoxy) quinolin-4-amine using docking and molecular dynamics simulation

Protein and Peptide Letters

Volumn 19, Issue 9, 2012, Pages 955-968

  Gupta, Shipra ^a   Misra, Gauri ^b   Pant, Mohan Chandra ^c   Seth, Prahlad Kishore ^a  

^a Biotech Park   (India)

^b Hygia Institute of Pharmaceutical Education and Research   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Activation loop; Apoptosis; Catalytic domain; Chemical fingerprint; Epidermal growth factor receptor protein; Molecular docking; Molecular interactions; Structural interaction fingerprinting

Indexed keywords

4 ANILINOQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; N (3 ETHYLPHENYL) 6,7 BIS(2 METHOXYETHOXY)QUINOLINE 4 AMINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PREDICTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMINOQUINOLINES; ANILINE COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CATALYTIC DOMAIN; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR DYNAMICS SIMULATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865765109     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986612802084456     Document Type: Article

References (55)

1. Mandal, M.; Younes, M.; Swan, E.A.; Jasser, S.A.; Doan, D.; Yigitbasi, O.; McMurphey, A.; Ludwick, J.; El-Naggar, A.K.; Bucana, C.; Mills, G.B.; Myers, J.N. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol., 2006, 42, 430-9.
2. Matta, A.; Ralhan, R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol., 2009, 1, 6. doi:10.1186/1758-3284-1-6.
3. Smirnova, T.; Adomako, A.; Locker, J.; Van Rooijen, N.; Prystowsky, M.B.; Segall, J.E. In vivo invasion of head and neck squamous cell carcinoma cells does not require macrophages. Am. J. Pathol., 2011, 178, 2857-65.
4. Romana, P.G. Cell alterations and molecular mechanisms in oral carcinogenesis. Int. J. Oral Maxillofac Surg., 2010.
5. Kim, S.; Grandis, J.R.; Rinaldo, A.; Takes, R.P.; Ferlito, A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck, 2008, 30, 667-74.
6. Ang, K.K.; Andratschke, N.H.; Milas, L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 959-65.
7. Rodemann, H.P.; Dittmann, K.; Toulany, M. Radiation-induced EGFR-signaling and control of DNA-damage repair. Int. J. Radiat. Biol., 2007, 83, 781-91.
8. Meyn, R.E.; Munshi, A.; Haymach, J.V.; Milas, L.; Ang, K.K. Receptor signaling as a regulatory mechanism of DNA repair. Radiother. Oncol., 2009, 92, 316-22.
9. Cruz-Lopez, O.; Conejo-Garcia, A.; Nunez, M.C.; Kimatrai, M.; Garcia-Rubino, M.E.; Morales, F.; Gomez-Perez, V.; Campos, J.M. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. Curr. Med. Chem., 2011, 18, 943-63.
10. Bussink, J.; van der Kogel, A. J.; Kaanders, J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol., 2008, 9, 288-96.
11. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J.H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 2002, 110, 775-87.
12. Garrett, T.P.; McKern, N.M.; Lou, M.; Elleman, T.C.; Adams, T.E.; Lovrecz, G.O.; Zhu, H.J.; Walker, F.; Frenkel, M.J.; Hoyne, P.A.; Jorissen, R.N.; Nice, E.C.; Burgess, A.W.; Ward, C.W. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor. Cell, 2002, 110, 763-73.
13. He, L.; Shobnam, N.; Hristova, K. Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain. Biochim. Biophys. Acta, 2011, 1808, 253-9.
14. Bergamin, E.; Hallock, P.T.; Burden, S.J.; Hubbard, S.R. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol. Cell, 2010, 39, 100-9.
15. Bae, J.H.; Schlessinger, J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol. Cells, 2010, 29, 443-8.
16. Stamos, J.; Sliwkowski, M.X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem., 2002, 277, 46265-72.
17. Bonner, J.A.; Yang, E.S.; Trummell, H.Q.; Nowsheen, S.; Willey, C.D.; Raisch, K.P. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother. Oncol., 2011, 99, 339-43.
18. Bruzzese, F.; Leone, A.; Rocco, M.; Carbone, C.; Piro, G.; Caraglia, M.; Di Gennaro, E.; Budillon, A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell Physiol., 2011, 226, 2378-90.
19. Yoshimasu, T.; Oura, S.; Ohta, F.; Hirai, Y.; Naito, K.; Nakamura, R.; Nishiguchi, H.; Hashimoto, S.; Kawago, M.; Okamura, Y. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J. Thorac. Oncol., 2011, 6, 1658-62.
20. Tartarone, A. Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. Future Oncol., 2010, 6, 1937-40.
21. Bikadi, Z.; Hazai, E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J. Cheminform., 2009, 1, 15.doi:10.1186/1758-2946-1-15.
22. Labute, P. Protonate 3D: Assignment of macromolecular protonation state and geometry. Chemical Computing Group Inc., 2007.
23. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-62.
24. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30, 2785-91.
25. Shaikh, S.A.; Ahmed, S.R.; Jayaram, B. A molecular thermodynamic view of DNA-drug interactions: a case study of 25 minor-groove binders. Arch. Biochem. Biophys., 2004, 429, 81-99.
26. Lee, M.S.; Olson, M.A. Calculation of absolute ligand binding free energy to a ribosome-targeting protein as a function of solvent model. J. Phys. Chem. B, 2008, 112, 13411-7.
27. Jenwitheesuk, E.; Samudrala, R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct. Biol., 2003, 3, 2. doi:10.1186/1472-6807-3-2.
28. Kumar, A.; Siddiqi, M.I. Virtual screening against Mycobacterium tuberculosis dihydrofolate reductase: suggested workflow for compound prioritization using structure interaction fingerprints. J. Mol. Graph. Model., 2008, 27, 476-88.
29. Singh, J.; Deng, Z.; Narale, G.; Chuaqui, C. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem. Biol. Drug Des., 2006, 67, 5-12.
30. Michaud-Agrawal, N.; Denning, E.J.; Woolf, T.B.; Beckstein, O. MDAnalysis: A toolkit for the analysis of molecular dynamics simulations. J. Comput. Chem., 2011, 10, 2319-27.
31. Yu, R.; Craik, D. J.; Kaas, Q. Blockade of neuronal alpha7-nAChR by alpha-conotoxin ImI explained by computational scanning and energy calculations. PLoS Comput. Biol., 2011, 7, e1002011.
32. Li, W.; Tang, Y.; Hoshino, T.; Neya, S. Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. J. Mol. Graph Model., 2009, 28, 170-6.
33. Tandon, A.; Sinha, S. Structural insights into the binding of MMP9 inhibitors. Bioinformation, 2011, 5, 10-4.
34. Petrov, K.G.; Zhang, Y.M.; Carter, M.; Cockerill, G.S.; Dickerson, S.; Gauthier, C.A.; Guo, Y.; Mook, R.A. Jr.; Rusnak, D.W.; Walker, A.L.; Wood, E.R.; Lackey, K.E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg. Med. Chem. Lett., 2006, 16, 4686-91.
35. Smith, L.; Wong, W.C.; Kiselyov, A.S.; Burdzovic-Wizemann, S.; Mao, Y.; Xu, Y.; Duncton, M.A.; Kim, K.; Piatnitski, E.L.; Doody, J.F.; Wang, Y.; Rosler, R.L.; Milligan, D.; Columbus, J.; Balagtas, C.; Lee, S.P.; Konovalov, A.; Hadari, Y.R. Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase. Bioorg. Med. Chem. Lett., 2006, 16, 5102-6.
36. Hughes, T.V.; Xu, G.; Wetter, S.K.; Connolly, P.J.; Emanuel, S.L.; Karnachi, P.; Pollack, S.R.; Pandey, N.; Adams, M.; Moreno-Mazza, S.; Middleton, S.A.; Greenberger, L.M. A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: design, synthesis, and biological activity. Bioorg. Med. Chem. Lett., 2008, 18, 4896-9.
37. Mostrag-Szlichtyng, A.; Worth, A. Review of QSAR models and software tools for predicting biokinetic properties. Luxembourg: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, 2010.
38. Waterson, A.G.; Stevens, K.L.; Reno, M.J.; Zhang, Y.M.; Boros, E.E.; Bouvier, F.; Rastagar, A.; Uehling, D.E.; Dickerson, S.H.; Reep, B.; McDonald, O.B.; Wood, E.R.; Rusnak, D.W.; Alligood, K.J.; Rudolph, S.K. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 2419-22.
39. Szabo, B.; Nelhubel, G.A.; Karpati, A.; Kenessey, I.; Jori, B.; Szekely, C.; Petak, I.; Lotz, G.; Hegedus, Z.; Hegedus, B.; Fule, T.; Dome, B.; Timar, J.; Tovari, J. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol., 2011, 47, 487-96.
40. Young, R.J.; Rischin, D.; Fisher, R.; McArthur, G.A.; Fox, S.B.; Peters, L.J.; Corry, J.; Lim, A.; Waldeck, K.; Solomon, B. Relationship between Epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 1230-7.
41. Marshall, M.E.; Hinz, T.K.; Kono, S.A.; Singleton, K.R.; Bichon, B.; Ware, K.E.; Marek, L.; Frederick, B.A.; Raben, D.; Heasley, L.E. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res., 2011, 17, 5016-25.
42. Choowongkomon, K.; Sawatdichaikul, O.; Songtawee, N.; Limtrakul, J. Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database. Molecules, 2010, 15, 4041-54.
43. Dunkel, M.; Günther, S.; Ahmed, J.; Wittig, B.; Preissner, R. SuperPred: drug classification and target prediction. Nucleic Acids Res., 2008, 36, W55-9.
44. Kumar, A.; Chaturvedi, V.; Bhatnagar, S.; Sinha, S.; Siddiqi, M.I. Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints. J. Chem. Inf. Model, 2009, 49, 35-42.
45. Gupta, S.; Misra, G.; Pant, M.C.; Seth, P.K. Prediction of a new surface binding pocket and evaluation of inhibitors against huntingtin interacting protein 14: an insight using docking studies. J. Mol. Model, 2011, 17, 3047-56.
46. Tian, G.; Haffner, C.D. Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5alpha-reductase by delta 1-4-azasteroids. J. Biol. Chem., 2001, 276, 21359-64.
47. De Bono, J.S.; Rowinsky, E.K. Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br. Med. Bull., 2002, 64, 227-54.
48. Kenessey, I. Study of motogenic signal in human melanoma cells. Magy Onkol., 2011, 55, 55-8.
49. Rasaiah, J.C.; Garde, S.; Hummer, G. Water in nonpolar confinement: from nanotubes to proteins and beyond. Annu. Rev. Phys. Chem., 2008, 59, 713-40.
50. Kartasasmita, R.E.; Herowati, R.; Gusdinar, T. Docking study of quercetin derivatives on inducible nitric oxide synthase and prediction of their absorption and distribution properties. J. Appl. Sci., 2010, 10, 3098-3104.
51. Pecsi, I.; Leveles, I.; Harmat, V.; Vertessy, B.G.; Toth, J. Aromatic stacking between nucleobase and enzyme promotes phosphate ester hydrolysis in dUTPase. Nucleic Acids Res., 2010, 38, 7179-86.
52. Dougherty, D.A. Cation-pi interactions involving aromatic amino acids. J. Nutr., 2007, 137, 1504S-17S.
53. Kreienkamp, H.J.; Utkin, Y.N.; Weise, C.; Machold, J.; Tsetlin, V.I.; Hucho, F. Investigation of ligand binding sites of the acetylcholine receptor using photoactivatable derivatives of neurotoxin II from Naja naja oxiana. Biochem., 1992, 31, 8239-8244.
54. Polticelli, F.; Ascenzi, P.; Bolognesi, M.; Honig, B. Structural determinants of trypsin affinity and specificity for cationic inhibitors. Protein Sci., 1999, 8, 2621-9.
55. Latha, P.P.D.; Sharmila, J.S.D. QSAR study for the prediction of IC50 and Log P for 5-N-Acetyl-Beta-D neuraminic acid structurally similar compounds using stepwise (multivariate) linear regression. Int. J. Chem. Res., 2010, 2, 32-8.